Evidence map›Paper›PMID 31190264›Full record

ArticleObesity surgery2019

Ketorolac Use Shortens Hospital Length of Stay After Bariatric Surgery: a Single-Center 5-Year Experience.

Kamyar Hariri, Elizabeth Hechenbleikner, Matthew Dong, Subhash U Kini, Gustavo Fernandez-Ranvier, Daniel M Herron

Abstract read
PubMed Publisher
In one paragraph

Article in Obesity surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kamyar HaririThe Garlock Division of General Surgery, Icahn School of Medicine at Mount Sinai Hospital, 5 East 98th Street, 3rd Floor, New York, NY, 10029, USA.
Elizabeth HechenbleiknerThe Garlock Division of General Surgery, Icahn School of Medicine at Mount Sinai Hospital, 5 East 98th Street, 3rd Floor, New York, NY, 10029, USA.
Matthew DongThe Garlock Division of General Surgery, Icahn School of Medicine at Mount Sinai Hospital, 5 East 98th Street, 3rd Floor, New York, NY, 10029, USA.
Subhash U KiniThe Garlock Division of General Surgery, Icahn School of Medicine at Mount Sinai Hospital, 5 East 98th Street, 3rd Floor, New York, NY, 10029, USA.
Gustavo Fernandez-RanvierThe Garlock Division of General Surgery, Icahn School of Medicine at Mount Sinai Hospital, 5 East 98th Street, 3rd Floor, New York, NY, 10029, USA.
Daniel M HerronThe Garlock Division of General Surgery, Icahn School of Medicine at Mount Sinai Hospital, 5 East 98th Street, 3rd Floor, New York, NY, 10029, USA. daniel.herron@mountsinai.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThere has been a recent increased interest in the use of non-steroidal anti-inflammatory drugs (NSAIDs) such as ketorolac for post-operative pain management to minimize opioid use and decrease hospital length of stay (LOS). Although NSAID use has been controversial following bariatric surgery due to anecdotal concerns for increased gastric bleeding, the impact of ketorolac as an adjunct to opioids needs further investigation on LOS and post-operative complications like bleeding.

objectiveThis study aims to evaluate the impact of post-operative ketorolac use on opioid consumption, LOS, and bleeding risk after bariatric surgery.

methodsWe retrospectively analyzed a prospectively maintained database of all bariatric surgery patients who either underwent sleeve gastrectomy (SG) or Roux-en-Y gastric bypass surgery (RYGB) at a tertiary center between 2011 and 2015. Patients were stratified into 2 groups based on post-operative pain control regimen as follows: (1) ketorolac and opioids and (2) opioids alone.

resultsA total of 1555 patients were identified who underwent either SG (n = 1255) or RYGB (n = 300). The overall LOS was 1.81 ± .059 days for ketorolac-opioid patients vs. 2.09 ± .065 days for opioid-only patients (P < 0.001). Furthermore, the risk of post-operative bleeding was similar between the two groups (P = 0.097).

conclusionPatients who received ketorolac as an adjunct to opioids had a significantly shorter LOS compared to opioid-only patients. Additionally, ketorolac use was not associated with increased risk of post-operative bleeding complications. Therefore, if not contraindicated, ketorolac should be considered routinely for post-operative pain control among bariatric surgery patients.

Indexed as

AdultAnalgesics, OpioidAnti-Inflammatory Agents, Non-SteroidalDrug Therapy, CombinationFemaleGastrectomyGastric BypassHumansKetorolacLength of StayMalePostoperative PainRetrospective StudiesAnalgesics, OpioidAnti-Inflammatory Agents, Non-SteroidalKetorolacBariatric surgeryBleedingKetorolacLength of stayOpioids

Identifiers

PMID31190264

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.